Immunity Pharma Announces Positive Top Line Results from Phase 2a Trial with IPL344 in ALS Patients
Jerusalem, Israel, January 16, 2024
- Treatment with IPL344 was well tolerated
- Changes in the slope of decline in ALSFRS-R demonstrated 48% slower disease progression
Neurofilament (NfL) Reduction Following IPL344 Treatment of ALS Patients
Jerusalem, Israel, December 10, 2023
- Indication of neurodegeneration slow down following IPL344 treatment
Immunity Pharma, a clinical-stage neurology-focused
...Immunity Pharma Announces Promising Interim Results of its Phase 1/2a Study with IPL344 in ALS
Jerusalem, Israel, September 10th 2020
- Early indications for clinically significant efficacy during IPL344 treatment of ALS patients (ALSFRS-R and SVC)
- IPL344
Immunity Pharma Announces that Its Novel ALS Treatment was Granted an Orphan Drug Designation by Both the FDA and the European Medicines Agency
Jerusalem, Israel, February 2, 2020
Immunity Pharma, a clinical-stage neurology-focused biopharmaceutical company, announced today that its novel ALS targeting drug IPL344 was granted an
...Immunity Pharma Announces Initiation of a Phase 1/2a Clinical Trial of IPL344 in Patients with ALS
Jerusalem, Israel, August 14 2018
Immunity Pharma, a clinical-stage neurology-focused biopharmaceutical company, announced today the initiation of a Phase 1/2a clinical trial of IPL344 in
...Immunity Pharma Announces Regulatory Approval for Phase 2a Follow-up Study in ALS
Jerusalem, Israel, February 6, 2018
Immunity Pharma, a clinical-stage neurology-focused biopharmaceutical company, announced today that the Israel's Ministry of Health (MOH) has approved
...Immunity Pharma Appoints Mr. Ron Pfeifer as Chairman of the Board
Jerusalem, Israel, October 1, 2017
Immunity Pharma, a privately-held neurology-focused biopharmaceutical company, announced today that Mr. Ron Pfeifer was appointed as the chairman of its
...Immunity Pharma Appoints Vice President of Research and Development
Jerusalem, Israel, July 27, 2017
Immunity Pharma, a neurology-focused biopharmaceutical company, announced today that Dr. Ilana Cohen has joined Immunity Pharma as its Vice President of
...Immunity Pharma Announces Passing a Two-Year Mark for Treating an ALS Patient with IPL344 under a Compassionate Treatment Protocol
Jerusalem, Israel, December 1, 2016
Immunity Pharma, a neurology-focused biopharmaceutical company, announced today that it has passed a two-year mark for treating an ALS patient with
...